The development of effective therapeutic interventions for neurodegeneration requires a better understanding of the early events that precede neuronal loss. Recent work in various disease models has begun to emphasize the significance of presynaptic dysfunction as an early event that occurs before manifestation of neurological disorders. Dysregulation of dopamine (DA) homeostasis is implicated in neurodegenerative diseases, drug addiction, and neuropsychiatric disorders. The neuronal plasma membrane dopamine transporter (DAT) is essential for the maintenance of DA homeostasis in the brain. α-synuclein is a 140-amino acid protein that forms a stable complex with DAT and is linked to the pathogenesis of neurodegenerative disease. In this review we will examine the prevailing hypotheses for α-synuclein-regulation of DAT biology.
. DAT functions in multiple modes of activity, forward (uptake), reverse (efflux), and channel mode. DAT shown to induce DA efflux via two independent mechanisms: a slow process consistent with an exchange mechanism and a process that results in rapid (millisecond) bursts of DA flux through a channel-like mode of DAT. Recent finding show that uptake, and efflux via DAT is independently regulated. Thus, it is possible that α-synuclein uniquely modulate DAT-mediated currents to activate cellular targets or conformational changes in the transporter protein that can alter the dimension and duration of synaptic DA. Figure 2 . The balance between intracellular and extracellular DA determines the synaptic DA concentration. α-synuclein over-expression decreases DA synthesis and uptake. The effect of α-Synuclein on DA efflux, a major factor in DA homeostasis is not fully understood. It is important to determine the mechanism and functional consequences of DAT/α-synuclein interaction on DAT-mediated DA efflux, and membrane distribution of the transporter.
In addition, natural substrate flux studies can also be confounded due to concomitant stimulation of pre-synaptic receptors (such as the auto-receptors) as during stimulation of D2 DA receptors (D2Rs) [57] [58] [59] . Therefore, examining DAT activity in its native environment or in heterologous expression system when D2R is blocked or removed via genetic manipulations [60] may confound the outcome since D2R is shown to interact with DAT and regulate the baseline and substrateinduced activity of the transporter [61] . and fine-tuned the methodology for utilization of ASP + to monitor DA uptake through DAT [62] [63] [64] .This approach was later adopted by other groups [61, 65, 66 ]. [87] [88] [89] . α-synuclein protein is also a major component of Lewy bodies, the hallmark pathological inclusions of PD [87] [88] [89] .
Therefore, α-synuclein plays an important role in the pathogenesis of familial and sporadic PD.
α-synuclein co-immunoprecipitates with DAT in both transfected cells and rat primary mesencephalic dopaminergic neurons, suggesting complex formation between Figure 3 . DAT mediates DA uptake and efflux, and assumes number of conformations with differing substrate binding abilities. It has been shown that a-synuclein overexpression decreases DAT-mediated DA uptake without an effect on surface DAT number. Does a-synuclein influence the ionic coupling of DAT, decrease the outward facing conformation of DAT and/or alter the rate of DA association and dissociation? these two proteins [90] [91] [92] . α-synuclein has a native monomeric state with no significant secondary structure [93] [94] [95] . The protein is believed to undergo a major structural change from its natively unfolded state to an α-helical conformation upon interaction with membrane lipids and is associated with the pre-synaptic neuronal membranes and has recently been reported to be associated with lipid rafts [87] [88] [89] 96] . Martinez et al, shown that α-synuclein specifically binds to ganglioside GM1-containing small unilamellar vesicles [97] .
Collectively the available data in the literature is consistent with the interpretation that α-synuclein may exist in the cell membrane regions rich in gangliosides and raft-like membrane domains in the synaptic terminals [97] . Thus, in pathological condition when the level of protein increases [87] [88] [89] , α-synuclein accumulation at the cell membrane can profoundly alter normal cell physiology.
Although it has been more than ten years that Frank Lee and his colleague shown α-synuclein interacts with trans-membrane proteins such as DAT [92] , the information on how α-synuclein affects the biology of DAT is still controversial and evolving [65] . α-synuclein and DAT complex formation appears to be dependent only on interaction with the last 22 amino acids of the C-terminal tail of DAT (Glu598-Val620) [92] (also Figure 2 ).
Utilizing electrophysiology, imaging, and molecular biology approaches Swant et al, have
shown that α-synuclein alters DA homeostasis by decreasing DA uptake, without an effect on the number DAT at the surface membrane [65] . However, the underlying mechanism for α-synuclein-mediated decrease in DA uptake via DAT is not understood (Figure 2 and 3 DAT is distributed in lipid rich and lipid poor membrane micro-domains [98] . The membrane micro-domain distribution of DAT has been
shown to affect its biology [98, 99] . Recently Table 1 summarizes known information about 
